Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30187261 | 0.82 | MAPT (0.44) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3471424 | 0.82 | MAPT (0.44) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL179720 | 0.81 | FTO (0.49) | MAPTMEN1KMT2AALDH1A1FTO | |
| SCHEMBL22050403 | 0.79 | MEN1 (0.42) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL29722 | 0.77 | CHRM3 (0.46) | MEN1KMT2AP2RX4P2RX1P2RX3 | |
| SCHEMBL13458772 | 0.76 | FTO (0.40) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14022367 | 0.76 | HPGD (0.39) | MAPTMEN1KMT2AALDH1A1FTO | |
| SCHEMBL3472059 | 0.76 | PDK2 (0.43) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL22050411 | 0.76 | HSD17B10 (0.42) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL30398085 | 0.76 | PDK2 (0.43) | MAPTMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230375558-A1 | Methods for Using Collagen Hybridizing Peptides to Determine Collagen Content | 3HELIX, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230364271-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | CORNELL UNIVERSITY | 2023-11-16 | — | — | US | disclosed |
| CN-116888143-A | Method for determining collagen content by using collagen hybrid peptide | 3螺旋有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4221763-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | Cornell University (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4217382-A1 | METHODS FOR USING COLLAGEN HYBRIDIZING PEPTIDES TO DETERMINE COLLAGEN CONTENT | 3Helix, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022072292-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | CORNELL UNIVERSITY (US) | 2022-04-07 | — | — | WO | disclosed |
| US-10941211-B2 | Anti-GCC antibody molecules and related compositions and methods | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-2490720-B1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARM INC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3520816-A2 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2841575-B1 | ANTI-GCC ANTIBODY MOLECULES AND USE OF SAME TO TEST FOR SUSCEPTIBILITY TO GCC-TARGETED THERAPY | MILLENNIUM PHARM INC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-4220450-A | Chemically induced fluorescence immunoassay | SYVA COMPANY (US) | 1980-09-02 | — | — | US | disclosed |
| US-4199559-A | DETERMINING THE PRESENCE OR AMOUNT OF A LIGAND OR ANTIBODIES | SYVA COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
| US-4174384-A | Fluorescence quenching with immunological pairs in immunoassays | SYVA COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4161515-A | DETECTING ANTILIGAND WITH LIGAND-ANALOG FLUORESCER | SYVA COMPANY (US) | 1979-07-17 | — | — | US | disclosed |
| US-4160016-A | Receptor fluorescent immunoassay | SYVA COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| US-4130462-A | Receptor steric hindrance immunoassay for receptor determination | SYVA COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-3998943-A | Double receptor fluorescent immunoassay | SYVA COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
| US-3996345-A | Fluorescence quenching with immunological pairs in immunoassays | SYVA COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3939350-A | Fluorescent immunoassay employing total reflection for activation | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1976-02-17 | — | — | US | disclosed |
| US-3935074-A | Antibody steric hindrance immunoassay with two antibodies | SYVA COMPANY (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941211-B2 | Anti-GCC antibody molecules and related compositions and methods | CD2BP2, UACA, COPG2 | MAPT 3294/4885MEN1 2481/4885KMT2A 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.